Citadel Advisors - XERIS BIOPHARMA HOLDINGS INC ownership

XERIS BIOPHARMA HOLDINGS INC's ticker is and the CUSIP is 98422E103. A total of 102 filers reported holding XERIS BIOPHARMA HOLDINGS INC in Q1 2022. The put-call ratio across all filers is 0.14 and the average weighting 0.3%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of XERIS BIOPHARMA HOLDINGS INC
ValueSharesWeighting
Q3 2023$600,955
-38.7%
323,094
-13.6%
0.00%
Q2 2023$979,618
+251.7%
373,900
+118.8%
0.00%
Q1 2023$278,567
-24.4%
170,900
-38.3%
0.00%
Q4 2022$368,463
-7.9%
277,040
+8.3%
0.00%
Q3 2022$400,000
-28.1%
255,750
-29.1%
0.00%
Q2 2022$556,000
-45.0%
360,923
-8.5%
0.00%
Q1 2022$1,010,000
-48.4%
394,414
-40.9%
0.00%
Q4 2021$1,956,000667,5470.00%
Other shareholders
XERIS BIOPHARMA HOLDINGS INC shareholders Q1 2022
NameSharesValueWeighting ↓
CAXTON CORP 6,039,028$15,460,00019.22%
Stonepine Capital Management, LLC 7,924,056$20,286,0008.41%
ARMISTICE CAPITAL, LLC 7,464,993$19,110,0000.37%
NEA Management Company, LLC 3,246,785$8,312,0000.24%
Alpine Global Management, LLC 633,040$1,620,0000.20%
DELTEC ASSET MANAGEMENT LLC 248,000$635,0000.11%
Redmile Group, LLC 1,046,587$2,679,0000.08%
CTC Capital Management, LLC 11,800$30,0000.08%
TUDOR INVESTMENT CORP ET AL 961,192$2,461,0000.06%
Yakira Capital Management, Inc. 117,076$300,0000.04%
View complete list of XERIS BIOPHARMA HOLDINGS INC shareholders